2342-P: Natural History of New Diabetes after COVID-19 Infection: The COVID-19 and Diabetes Assessment (CODA) Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2342-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JENNIFER G. LYONS und 11 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: COVID-19 infection has been associated with an increased risk of diabetes mellitus (DM). Limited data is available regarding whether patients with COVID-19 infection preceding DM have different disease severity than those without a prior infection. The goal of this study was to assess diabetes-related outcomes among patients with positive vs. negative COVID-19 tests prior to a new diagnosis.
Methods
We conducted a retrospective cohort study using electronic health record data from 31 healthcare systems participating in the PCORnet national research network and the NIH RECOVER program. Eligible patients were 20-80 years old with a COVID-19 test (positive or negative) prior to a new DM diagnosis from March 2020 to December 2022. Outcomes were HbA1c at DM diagnosis, healthcare utilization, and long-acting insulin use in the 365 days after diagnosis. Adjusted multivariable linear and logistic regression analyses evaluated the association between COVID-19 infection (i.e., positive test) and these outcomes.
Results
A total of 26,936 patients were diagnosed with new DM after a COVID-19 test (19% positive, 81% negative). We found little association between test result and mean HbA1c (estimated mean HbA1c difference: 0.09, 95% CI: 0.01, 0.16), though HbA1c was higher among patients diagnosed 50-200 days after testing positive. A positive test was associated with a lower risk of an inpatient encounter (OR: 0.84, 95% CI: 0.78 - 0.90) and a higher risk of an emergency department encounter (OR: 1.15, 95% CI: 1.08, 1.23). No difference was evident in long-acting insulin use (OR: 1.02, 95% CI: 0.88 - 1.18).
Conclusion
Shorter latency between COVID-19 infection and DM diagnosis was associated with slightly higher HbA1c. COVID-19 infection was associated with modest differences in health care utilization, but no difference in long-acting insulin use. More research is needed to further evaluate the nature of the association between COVID-19 and DM progression. Disclosure J.G. Lyons: None. S. Rifas-Shiman: None. J.G. Young: None. T. Eggerman: None. B. French: None. M. Hivert: None. S. McGrath: None. A.C. Powers: None. B. Rasouli: None. R.L. Rothman: Research Support; Current; Dexcom, Inc. J.S. Schildcrout: None. J.P. Block: None. Funding National Institutes of Health, NIDDK (U01DK137533)
Zitieren
APA
LYONS, J. G., RIFAS-SHIMAN, S., YOUNG, J. G., EGGERMAN, T., FRENCH, B., HIVERT, M., MCGRATH, S., POWERS, A. C., RASOULI, B., ROTHMAN, R. L., SCHILDCROUT, J. S., & BLOCK, J. P. (2026). 2342-P: Natural History of New Diabetes after COVID-19 Infection: The COVID-19 and Diabetes Assessment (CODA) Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2342-p
Vancouver
LYONS JG, RIFAS-SHIMAN S, YOUNG JG, EGGERMAN T, FRENCH B, HIVERT M, et al. 2342-P: Natural History of New Diabetes after COVID-19 Infection: The COVID-19 and Diabetes Assessment (CODA) Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2342-p
BibTeX
@article{LYONS2026,
author = {LYONS, JENNIFER G. and RIFAS-SHIMAN, SHERYL and YOUNG, JESSICA G. and EGGERMAN, THOMAS and FRENCH, BENJAMIN and HIVERT, MARIE-FRANCE and MCGRATH, SEAN and POWERS, ALVIN C. and RASOULI, BAHAREH and ROTHMAN, RUSSELL L. and SCHILDCROUT, JONATHAN S. and BLOCK, JASON P.},
title = {2342-P: Natural History of New Diabetes after COVID-19 Infection: The COVID-19 and Diabetes Assessment (CODA) Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2342-p}
}
EUVIMED